Royalty Report: Drugs, cardiac, Pain – Collection: 256997


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • cardiac
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 256997

License Grant
The Canadian University granted the Canadian Issuer an exclusive, world-wide license to use and, subject to the consent of the University, sublicense the Technology, and any improvements thereto, for antiarrhythmic and local anaesthetic uses, and to manufacture, distribute and sell products derived therefrom to the general public during the term of the University License Agreement.
License Property
Antiarrhythmic Project – the core therapeutic focus is the research and development of drugs which treat cardiac arrhythmias and prevent Sudden Cardiac Death.  Antiarrhythmic, an agent which has the ability to decrease the incidence of arrhythmia.  Arrhythmia is an abnormal electrical signal in the heart, or an abnormal heart beat resulting from such a signal.

Anaesthetics drugs which block the transmission of impulses; (local).  The Cough Project – Aerosolized lidocaine (a local anaesthetic) may be used clinically to create numbness in the lungs which somewhat lessens the coughing compulsion.

Field of Use
This agreement pertains to the drug industry

IPSCIO Record ID: 134564

License Grant
Licensee was granted exclusive rights by the Issuer to make, and have made, promote, sell and distribute the Canadian Issuers clinical compound RSD921 in the Peoples Republic of China, Taiwan and any of the member countries of ASEAN (the Territory).
License Property
The Phase II clinical trial provided 'proof of concept' data supporting the use of RSD921 in man.

The compound, RSD921, is an excellent local anaesthetic, featuring rapid onset and an attractive safety profile.

The RSD921 Local Anaesthetic Project – Local anaesthetic drugs work by reversibly interrupting the conduction of impulses in peripheral nerves.  Local anaesthetics can be applied directly on the skin and mucous membranes for superficial surgery, or be used to block pain impulses by means of injection near the nerve tracts or spinal cord, preventing the pain signal from being relayed to the central nervous system.

Field of Use
This agreement pertains to the drug industry

IPSCIO Record ID: 359108

License Grant
Canadian Licensor granted Licensee the sole, exclusive, irrevocable license to patented nanotechnologies for use with any drugs including cannabinoids,  to develop and optimize a proprietary nanoformulation of pharmaceutical cannabidiol, designed to avoid first-pass metabolism and improve bioavailability, for the treatment of heart failure.
License Property
Nanotechnologies are designed to improve solubilization, pharmacokinetics, and drug targeting of lipophilic drugs. Nanotechnologies is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes.

Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.

Field of Use
The license to patented nanotechnologies is for use with any drugs or classes of drugs currently used or developed in the future to diagnose or treat heart failure and/or any cardiovascular disease and/or cardiopulmonary disease and/or cardiac arrhythmias.

Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.